- Trail-blazing diversification of the repurposing of
Niclosamide
- Full-scale clinical preparation of injections for severely ill
patients
SEOUL, South Korea,
April 19, 2021 /PRNewswire/ --
Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company,
announced on the 19th that its major shareholding bio
tech company, CNPharm's single administration of 'Poly-COV01',
which was developed as an injection for severely ill patients with
the novel coronavirus infection (COVID- 19), was the first to
sustain an effective concentration in the blood that inhibits virus
activity by 100% (IC100) for more than 24 hours.
Poly-COV01, which is made by combining Niclosamide, an
anthelmintic drug, with CNPharm's world-class drug delivery system
(DDS) technology, is equipped with a sustained-release function
that continuously releases drugs loaded in the delivery system into
the blood. According to Hyundai Bioscience, if the dosage is
adjusted, the possibility of even curing severely ill COVID-19
patients with a single injection has increased.
According to CNPharm, in an experiment conducted on animals at
Knotus, its non-clinical Contract Research Organization (CRO), when
2mg/kg of Poly-COV01 was administered, the concentration of IC100
or higher was maintained in the blood for more than 24 hours, and
it was confirmed that the drug in the delivery system was
continuously released during this time. (Human clinical trials are to be
planned.)
There has not been an official foreign or domestic report of an
intravenous vascular injection like Poly-COV01 where the IC100
concentration of Niclosamide in the blood lasted for more than 24
hours, let alone with its sustained-release capability.
CNPharm has decided to begin clinical trial preparations of
Poly-COV01, which was developed for severely ill patients, using
Niclosamide as a base drug. Niclosamide is attracting much
international attention as a potential candidate for the treatment of COVID-19 as research papers and
experimental results indicating that it has excellent treatment
efficacy against COVID-19 have been released worldwide.
Nature, the world-class scientific journal, released a paper by a European research team
that selected Niclosamide as the best drug that can block lung
damage caused by COVID-19 infections and even introduced the
mechanism of blocking the formation of cell fusion bodies.
CNPharm stated that it has been successful in this experiment
because it has dramatically improved the problem of low absorption
rate and the short half-life of the concentration of Niclosamide in
the body by using CNPharm's original delivery system technology,
and also mentioned that following the oral drug, it was decided to
conduct various antiviral efficacy tests for the clinical use of
the injection system.
CNPharm's drug delivery system is based on the original
technology of Choy Jin-Ho, Chair
Professor of Dankook University and former Chair Professor
Sohn Yeon-Su of Ewha Womans
University. In addition to being introduced in Nature in
2001, related technologies have been published through several
SCI-level (Scientific Citation Index) papers over the past 20
years.
About Hyundai Bioscience
HYUNDAI BIOSCIENCE is a biotechnology company that develops and
commercializes bio-fusion technology with the purpose of delivering
active ingredients safely and efficiently to targeted areas of the
body. Hyundai Bioscience's Organic-Inorganic Hybrid Technology is a
novel drug delivery system technology that allows the selective and
effective delivery of active substances on the target area in
combination with bio-friendly delivery vehicles. Applying its
technology in the fields of tumor-targeted drugs and even skin
& scalp care, Hyundai Bioscience will continue to expand its
business scope by introducing innovative biotechnology and new
effective products.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cnpharm-has-succeeded-in-maintaining-ic100-for-24-hours-with-one-injection-301271503.html
SOURCE Hyundai Bioscience